We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00211705
First Posted: September 21, 2005
Last Update Posted: December 4, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Daiichi Sankyo Co., Ltd.
Ministry of Health, Labour and Welfare, Japan
Information provided by:
Mitsukoshi Health and Welfare Foundation
  Purpose
To evaluate the primary preventive effect of low-dose pravastatin against coronary heart disease (CHD) in Japanese hypercholesterolemic patients.

Condition Intervention Phase
Hyperlipidemia Behavioral: Diet Drug: Diet+pravastatin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA Study)

Resource links provided by NLM:


Further study details as provided by Mitsukoshi Health and Welfare Foundation:

Primary Outcome Measures:
  • Coronary Heart Disease(CHD)[fatal/non-fatal MI, sudden/cardiac death, angina, revascularization]

Secondary Outcome Measures:
  • Stroke, cerebrovascular infarction(CI), CHD+CI, all cardiovascular events, total mortality

Estimated Enrollment: 8000
Study Start Date: February 1994
Estimated Study Completion Date: March 2004
Detailed Description:
MEGA Study is the first prospective, randomized, controlled trial conducted in Japan to evaluate the primary preventive effect of pravastatin against CHD in daily clinical practice. Because the dose of pravastatin used in the MEGA Study was 10–20 mg/day, which is consistent with the approved doses in Japan and lower than the doses used in previous large-scale clinical trials.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • TC:220~270mg/dl
  • Male: 40-70 years old/ female: postmenopausal-70 years old
  • <40kg in weight

Exclusion Criteria:

  • FH
  • History of CHD(angina, MI, post-PTCA/CABG, etc.)
  • History of CVA(stroke, TIA, etc.)
  • Underlying malignant tumor
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00211705


Sponsors and Collaborators
Mitsukoshi Health and Welfare Foundation
Daiichi Sankyo Co., Ltd.
Ministry of Health, Labour and Welfare, Japan
Investigators
Study Chair: Haruo Nakamura, MD Mitsukoshi Health and Welfare
  More Information

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00211705     History of Changes
Other Study ID Numbers: MEGA
First Submitted: September 13, 2005
First Posted: September 21, 2005
Last Update Posted: December 4, 2006
Last Verified: June 2005

Keywords provided by Mitsukoshi Health and Welfare Foundation:
Hyperlipidemia
coronary heart disease
prevention
stroke
pravastatin

Additional relevant MeSH terms:
Hyperlipidemias
Hyperlipoproteinemias
Hypercholesterolemia
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Pravastatin
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors